Neurotech International Ltd (ASX: NTI) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Neurotech International Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$17.50 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.30 billion
Earnings per share
-0.010
Dividend per share
N/A
Year To Date Return
3.57%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Neurotech International Ltd (ASX: NTI)
Latest News
No posts found.
NTI ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Neurotech International Ltd
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
NTI Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 09 Feb 2026 | $0.01 | $0.00 | 0.00% | 30,600 | $0.01 | $0.01 | $0.01 |
| 06 Feb 2026 | $0.01 | $0.00 | 0.00% | 777,956 | $0.02 | $0.02 | $0.01 |
| 05 Feb 2026 | $0.02 | $0.00 | 0.00% | 3,549,646 | $0.02 | $0.02 | $0.01 |
| 04 Feb 2026 | $0.01 | $0.00 | 0.00% | 1,057,548 | $0.01 | $0.01 | $0.01 |
| 03 Feb 2026 | $0.01 | $0.00 | 0.00% | 10,334,222 | $0.01 | $0.01 | $0.01 |
| 02 Feb 2026 | $0.01 | $0.00 | 0.00% | 4,532,467 | $0.01 | $0.01 | $0.01 |
| 30 Jan 2026 | $0.01 | $0.00 | 0.00% | 4,136,692 | $0.02 | $0.02 | $0.01 |
| 29 Jan 2026 | $0.02 | $0.00 | 0.00% | 110,290 | $0.02 | $0.02 | $0.01 |
| 28 Jan 2026 | $0.02 | $0.00 | 0.00% | 940,626 | $0.02 | $0.02 | $0.02 |
| 27 Jan 2026 | $0.02 | $0.00 | 0.00% | 1,179,766 | $0.01 | $0.02 | $0.01 |
| 23 Jan 2026 | $0.01 | $0.00 | 0.00% | 1,083,674 | $0.02 | $0.02 | $0.01 |
| 22 Jan 2026 | $0.02 | $0.00 | 0.00% | 2,007,873 | $0.01 | $0.02 | $0.01 |
| 21 Jan 2026 | $0.01 | $0.00 | 0.00% | 2,073,375 | $0.01 | $0.01 | $0.01 |
| 20 Jan 2026 | $0.01 | $0.00 | 0.00% | 54,789 | $0.01 | $0.01 | $0.01 |
| 19 Jan 2026 | $0.01 | $0.00 | 0.00% | 147,287 | $0.01 | $0.01 | $0.01 |
| 16 Jan 2026 | $0.01 | $0.00 | 0.00% | 850,292 | $0.01 | $0.02 | $0.01 |
| 15 Jan 2026 | $0.01 | $0.00 | 0.00% | 992,250 | $0.02 | $0.02 | $0.01 |
| 14 Jan 2026 | $0.01 | $0.00 | 0.00% | 205,803 | $0.01 | $0.01 | $0.01 |
| 13 Jan 2026 | $0.01 | $0.00 | 0.00% | 4,212,340 | $0.02 | $0.02 | $0.01 |
| 12 Jan 2026 | $0.01 | $0.00 | 0.00% | 337,747 | $0.01 | $0.01 | $0.01 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 23 Dec 2025 | Gerald Quigley | Expiry | 5,000,000 | $80,000 |
Options expired.
|
| 24 Feb 2025 | Anthony Filippis | Issued | 20,000,000 | $800,000 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Robert (Max) Maxwell Johnston | Non-Executive Director | Apr 2024 |
Mr Johnston held the position of President and Chief Executive officer of Johnson and Johnson Pacific. Prior to this appointment, his career included several positions within Johnson and Johnson, both within Australia and overseas encompassing Europe and Asia. His career also included senior roles within Australia and overseas with Unilever and Guinness-United Distillers and several industry body roles as past President of ACCORD Australasia Limited, Vice Chairman of AFGC, and Board Member of ASMI.
|
| Mr Mark Davies | Non-Executive DirectorNon-Executive Chairman | Apr 2019 |
Mr Davies has over 20 years' experience in trading, investment banking and providing corporate advice. He worked at Montagu Stockbrokers before co-founding investment banking firm Cygnet Capital and more recently 1861 Capital. He specializes in providing corporate advice and capital raising services to emerging companies seeking business development opportunities and funding from the Australian market.
|
| Mr Gerald Quigley | Non-Executive DirectorDirector of Public Relations | Jul 2022 |
Mr Quigley is a pharmacist and consumer health commentator. As a media health commentator heard each week on television and radio stations across Australia. He has knowledge relating to pharmaceutical and nutraceutical product development, dispensing & marketing in addition to product positioning within the relevant regulatory landscapes (e.g. TGA, FDA).
|
| Mr Anthony Filippis | Chief Executive OfficerManaging Director | Feb 2025 |
Dr Filippis has 25 years of leadership experience across the biotechnology, healthcare, and investment sectors in therapeutic areas, including neuroscience, oncology, and endocrinology, with a particular focus on commercializing innovative clinical therapeutics for diseases with high unmet medical need. Over the course of his career, Anthony has held senior roles at several ASX-listed and private life sciences companies.
|
| Ms Alessandra Gauvin | Company Secretary | Mar 2024 |
-
|
| Alessandra Gauvin | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited A/C 2 | 85,757,592 | 8.17% |
| J&J Bandy Nominees Pty Ltd <Bandy P/F A/C> | 43,996,178 | 4.19% |
| Jalaver Pty Ltd <Falcon Pension A/C> | 42,000,000 | 4.00% |
| Dutch Ink (2010) Pty Ltd | 37,000,000 | 3.53% |
| The Trust Company (Australia) Limited <MOF A/C> | 30,506,500 | 2.91% |
| Chincherinchee Nominees Pty Ltd | 27,693,572 | 2.64% |
| Citicorp Nominees Pty Limited | 22,427,704 | 2.14% |
| Mrs Melanie Therese Verheggen | 18,017,328 | 1.72% |
| MB Investment Capital Pty Ltd | 17,084,226 | 1.63% |
| Gofour Sail Pty Ltd | 17,073,000 | 1.63% |
| Netwealth Investments Limited <Wrap Services A/C> | 16,811,765 | 1.60% |
| Fenix Innovation Group Pty Ltd | 15,245,311 | 1.45% |
| Buttonwood Nominees Pty Ltd | 13,259,307 | 1.26% |
| Mr Vedat Isikgel | 12,649,999 | 1.21% |
| Britoak Pty Ltd | 12,556,351 | 1.20% |
| Mr Patrick Pasquale Steve Calabria <Dolce Elite A/C> | 12,000,000 | 1.14% |
| Quadrangle Capital Pty Ltd | 11,900,000 | 1.13% |
| Seivad Investments Pty Ltd <Davies Family A/C> | 11,793,017 | 1.12% |
| Max Cap Investments Pty Ltd | 11,080,000 | 1.06% |
| The Sun W Investment Pty Ltd <Sun Family A/C> | 11,027,272 | 1.04% |
